Items Tagged ‘Chronic Myeloid Leukemia’

June 14th, 2017

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia

By

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended the lives of patients with the condition and, in many ways, ushered in the era of molecularly-targeted treatments against cancer. […]

View full entry

Tags: BCR-ABL, Chronic Myeloid Leukemia, CML, dasatinib), Gleevec, imatinib, Leukemia, News, Philadelphia chromosome Sprycel


May 2nd, 2017

Have a Question about Chronic Myeloid Leukemia? Join us on May 25th!

By

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Luskin CancerConnect announces the opportunity to engage with leukemia expert, Marlise Luskin, MD, MSCE. On May 25th, 2017, Dr. Luskin will answer your pre-submitted questions about chronic myeloid leukemia (CML) on CancerConnect. CancerConnect is an online support community for individuals affected by cancer. Dr. Luskin […]

View full entry

Tags: Chronic Myeloid Leukemia, cml expert, expert, Leukemia, News


December 14th, 2016

FDA Grants Iclusig® Expanded Approval for CML

By

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are not eligible for treatment with another tyrosine kinase inhibitor. The approval indication also includes adults with T3151-positive CML and T3151-positive […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, CML, Iclusig, Leukemia, News, PACE trial, Ph+ ALL, ponatinib, TKI, tyrosine kinase inhibitor


April 7th, 2015

Tasigna® Remains Superior to Gleevec® for Treatment of Newly Diagnosed Patients With Chronic Myeloid Leukemia

By

Tasigna® (nilotinib) remains superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (PH+CML), according to the results of the six-year update from the ENESTnd trial which were presented at the 56th annual meeting of the American Society of Hematology (ASH) in San Francisco.  These data are consistent with that […]

View full entry

Tags: Chronic Myeloid Leukemia, CML, ENESTnd trial, Gleevec, imatinib, Leukemia, News, nilotinib, Philadelphia chromosome positive, Tasigna


February 21st, 2014

SYNRIBO® Approved for use in Chronic Myeloid Leukemia

By

The U.S. Food and Drug Administration (FDA) has granted full approval of SYNRIBO® (omacetaxine mepesuccinate) for injection. SYNRIBO is indicated for adult patients with chronic phase (CP +0.28%, news) or accelerated phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).  SYNRIBO® is indicated for the treatment […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


January 4th, 2013

Iclusig Approved for CML and ALL

By

The U.S. Food and Drug Administration (FDA) has approved Iclusig™ (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases. Chronic myeloid leukemia (CML) is the abnormal growth of relatively mature myeloid (white blood) cells. Acute lymphoblastic leukemia (ALL) is a […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, News


December 21st, 2012

Tasigna Superior to Gleevec for Philadelphia Chromosome-Positive CML

By

Tasigna® (nilotinib) is superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML), according to the results of two studies presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. Each year in the United States, approximately 5,000 people are diagnosed with chronic myeloid […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


November 8th, 2012

Synribo Approved for CML

By

The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults. Each year in the United States, approximately 5,000 people are diagnosed with CML. Most cases of CML are characterized by a chromosomal abnormality—the Philadelphia chromosome—in […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


September 26th, 2012

Bosulif Approved for CML

By

The U.S. Food and Drug Administration (FDA) has approved Bosulif® (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults. The drug is intended for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML who are resistant to or who cannot tolerate other therapies, including […]

View full entry

Tags: Chronic Myeloid Leukemia, News


August 13th, 2012

Ponatinib Produces High Response Rates in CML

By

Ponatinib, an investigational targeted agent, appears to be significantly effective in treatment-refractory chronic myeloid leukemia (CML) and produces early and lasting responses, according to the preliminary results of a study presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. Each year in the United States, approximately 5,000 […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


October 17th, 2011

New Warning Added to Sprycel Label

By

The US Food and Drug Administration (FDA) announced that Sprycel® (dasatinib) may increase the risk of a rare but serious condition known as pulmonary arterial hypertension. Sprycel is a targeted therapy used to treat selected adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL). Pulmonary arterial hypertension (PAH) is a […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Leukemia, News


October 14th, 2011

Bosutinib Shows Promise for Second-Line CML Treatment

By

Treatment with the investigational drug bosutinib produced promising rates of response among patients with chronic-phase chronic myeloid leukemia (CML) that had previously been treated with Gleevec® (imatinib). The results of this Phase I/II trial were published in Blood. Each year in the United States, approximately 5,000 people are diagnosed with CML. Most cases of CML […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


September 7th, 2011

Tasigna Continues to Show Benefit for Newly Diagnosed CML

By

According to updated results from a Phase III clinical trial, Tasigna® (nilotinib) continues to be more effective than Gleevec® (imatinib) for the initial treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. These results were published in Lancet Oncology. Each year in the United States, approximately 5,000 […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


June 17th, 2011

Bosutinib Evaluated for Initial Treatment of Patients with CML

By

Researchers involved in an international study have reported that a new tyrosine kinase inhibitor, bosutinib, appears to be superior to Gleevec® (imatinib) for the initial therapy of patients with chronic myeloid leukemia (CML). The early results of this randomized trial were presented at the 2011 meeting of the American Society of Clinical Oncology. Each year […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia, News


May 23rd, 2011

Many Patients with “Chemo Brain” Recover within Five Years

By

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist for more than five years after treatment. These findings were recently reported in the Journal of Clinical Oncology. Chemo brain refers […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adult Acute Lymphoblastic Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Allogeneic Stem Cell Transplant, Childhood Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Early Stage Hodgkin's Lymphoma